Niraparib after surgery for ovarian cancer with limited spread
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial is testing a second course of niraparib (a PARP inhibitor) after surgery for ovarian cancer that has come back in just a few spots. It aims to see if restarting niraparib can help keep the cancer from coming back again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman 18 or older with high-grade serous or endometrioid ovarian cancer.
- The cancer came back in only 1 to 5 spots while you were on a PARP inhibitor (like niraparib) maintenance therapy.
- You had surgery to remove those spots, and the surgeon was able to remove all visible cancer.
- You had good benefit from the PARP inhibitor (at least 12 months of treatment) before the cancer returned.
- You are willing to provide tumor tissue from your surgeries and blood samples for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well the drug niraparib works as a maintenance treatment for women with advanced ovarian cancer that responded well to initial platinum-based chemotherapy. It may help keep the cancer from coming back.
This study looks at how well niraparib works as maintenance therapy for women with advanced ovarian, fallopian tube, or primary peritoneal cancer who have already responded to initial chemotherapy. It aims to gather real-world data on the treatment's effectiveness and safety.
This trial tests whether a different starting dose (and adjustments) of niraparib can help people with advanced ovarian (or related) cancer stay on treatment without as many dose interruptions. It’s designed for people who have already finished first-line chemotherapy and whose cancer responded.
This trial tests whether olaparib (a pill cancer medicine) works better than standard platinum chemotherapy after a second surgery for recurrent ovarian cancer. It’s for people whose cancer returned after initial PARP-inhibitor (PARPi) maintenance and aims to see if treatment can control the cancer for longer with acceptable side effects.
This trial studies whether niraparib works better when combined with bevacizumab after chemotherapy and surgery for advanced ovarian, fallopian tube, or peritoneal cancer. If you qualify, you may help researchers find a treatment plan that controls the cancer for longer.
This trial tests whether niraparib, taken after surgery, works better when combined with bevacizumab in people with advanced ovarian, fallopian tube, or primary peritoneal cancer who have no visible tumor left. It also aims to see if this approach helps prevent the cancer from coming back.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.